Successful use of casirivimab/imdevimab anti-spike monoclonal antibodies to enhance neutralizing antibodies in a woman on anti-CD20 treatment with refractory COVID-19

Yusuke Miyazato; Kei Yamamoto; Yuichiro Nakaya; Shinichiro Morioka; Junko S Takeuchi; Yuki Takamatsu; Kenji Maeda; Moto Kimura; Wataru Sugiura; Hiroaki Mitsuya; Masao Yano; Norio Ohmagari

doi:10.1016/j.jiac.2022.03.002

Successful use of casirivimab/imdevimab anti-spike monoclonal antibodies to enhance neutralizing antibodies in a woman on anti-CD20 treatment with refractory COVID-19

J Infect Chemother. 2022 Jul;28(7):991-994. doi: 10.1016/j.jiac.2022.03.002. Epub 2022 Mar 23.

Authors

Affiliations

¹ Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, 162-8655, Japan.
² Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, 162-8655, Japan. Electronic address: kyamamoto@hosp.ncgm.go.jp.
³ Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, 162-8655, Japan; Division of Infectious Diseases, Shizuoka Cancer Center Hospital and Research Institute, Shizuoka, 411-8777, Japan.
⁴ Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, 162-8655, Japan.
⁵ Department of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute, Tokyo, 162-0052, Japan.
⁶ Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, 162-8655, Japan; Department of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute, Tokyo, 162-0052, Japan.
⁷ Department of Surgery, Minamimachida Hospital, Tokyo, 194-0004, Japan.

Abstract

Management of COVID-19 patients with humoral immunodeficiency is challenging. We describe a woman with COVID-19 with multiple relapses due to anti-CD20 monoclonal antibody treatment. She was successfully treated with casirivimab/imdevimab and confirmed to have neutralizing antibodies. This case suggests that monoclonal antibodies have therapeutic and prophylactic value in patients with humoral immunodeficiency.

Keywords: Anti-CD20 monoclonal antibody; COVID-19; Casirivimab/imdevimab; Neutralizing monoclonal antibody; Relapse; Rituximab.

MeSH terms

Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized
Antibodies, Neutralizing / therapeutic use
Antineoplastic Agents, Immunological*
COVID-19 Drug Treatment*
Female
Humans
SARS-CoV-2

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antibodies, Neutralizing
Antineoplastic Agents, Immunological
imdevimab
casirivimab